Skip to content

Could interactions with other antiretrovirals cause ‘tenofovir-associated’ kidney disease?

Risk of altered blood fat levels varies according to ethnic background, study shows

Fatigue may be misdiagnosed as depression during anti-HCV therapy in HIV coinfected

Fat loss associated with Combivir but not Truvada

Unusual abacavir hypersensitivity reaction involving severe respiratory symptoms reported

ICAAC: Switch from AZT or d4T to tenofovir may improve blood fat levels

ICAAC: Nevirapine’s manufacturer examines rates of liver toxicity in key study, finds once daily dose equally safe at lower CD4 count

ICAAC: Factors unrelated to HIV or side-effects of HIV treatment major cause of illness in French cohort

ICAAC: Pilot study shows dual protease inhibitor regimen as safe and effective as traditional two class HIV therapy